Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Regenxbio (RGNX) Gross Profit (2016 - 2024)

Regenxbio has reported Gross Profit over the past 11 years, most recently at $14.9 million for Q4 2024.

  • Quarterly results put Gross Profit at $14.9 million for Q4 2024, up 35.73% from a year ago — trailing twelve months through Dec 2024 was $49.8 million (down 6.16% YoY), and the annual figure for FY2024 was $49.8 million, down 6.16%.
  • Gross Profit for Q4 2024 was $14.9 million at Regenxbio, up from $11.8 million in the prior quarter.
  • Over the last five years, Gross Profit for RGNX hit a ceiling of $375.6 million in Q4 2021 and a floor of $6.5 million in Q1 2022.
  • Median Gross Profit over the past 5 years was $13.7 million (2021), compared with a mean of $34.9 million.
  • Biggest five-year swings in Gross Profit: skyrocketed 3257.14% in 2021 and later crashed 95.06% in 2022.
  • Regenxbio's Gross Profit stood at $11.2 million in 2020, then skyrocketed by 3257.14% to $375.6 million in 2021, then crashed by 95.06% to $18.6 million in 2022, then crashed by 40.87% to $11.0 million in 2023, then surged by 35.73% to $14.9 million in 2024.
  • The last three reported values for Gross Profit were $14.9 million (Q4 2024), $11.8 million (Q3 2024), and $11.7 million (Q2 2024) per Business Quant data.